Loading patent…
AssigneeChildren's Medical Center Corporation
InventorsCharles Berde, Daniel S. Kohane
Estimating the term…
Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were conducted to identify dosages of neosaxitoxin (“NeoSTX”) and bupivacaine, alone or in combination with epinephrine, to provide two to three days of pain relief in humans. Bupivacaine-NeoSTX combinations produce more reliable blockade and longer duration blockade compared to NeoSTX alone. The three-way combination of NeoSTX-bupivacaine-epinephrine produces more prolonged local anesthesia than the two-way combination of NeoSTX-bupivacaine. Addition of epinephrine to this NeoSTX-bupivacaine combination dramatically prolongs the duration of complete blockade to a mechanical stimulus. These results led to development of specific combination dosage formulations.
A method of making a dosage unit or kit for treatment or prevention of pain in a human, comprising providing neosaxitoxin, local anesthetic, epinephrine, and a diluent to produce the dosage unit or kit consisting of
A method of making a kit to provide a dosage unit for treatment or prevention of pain in a human, comprising providing a kit comprising neosaxitoxin, local anesthetic, epinephrine and a diluent to produce a dosage unit consisting of
Dependencies are inferred from the claim text.